Stalking behaviors and Personality Disorders: A systematic review.

Clin TerJan 1, 2026
Clinical ResearchPsychiatry

Emma Flutti, Giulia Moretti, Corinna Antonini et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined personality disorders (PDs) in mixed clinical-forensic populations with stalking behavior. Following a search of Medline/PubMed and Scopus, 12 papers were included from an initial 200; the reviewed studies covered 2378 people with stalking behavior, 14% of whom were female. The review found a higher prevalence of PDs among stalkers, particularly Cluster B disorders. PDs were also associated with recurrent stalking, while evidence about their role in violent behavior was inconsistent. The authors describe PD diagnosis as a risk factor associated with stalking behavior.

Key findings

  • The review included 12 papers from an initial 200 and covered 2378 people with stalking behavior; 14% were female.
  • PDs, particularly Cluster B disorders, were more prevalent among people with stalking behavior.
  • PDs appeared associated with recurrent stalking, but findings on their role in violent behavior were inconsistent.

Why it matters

The findings suggest that personality profiles may be relevant when assessing stalking behavior and recurrence. However, the inconsistent evidence concerning violence means PDs should not be treated as a reliable indicator of violent behavior. The review highlights the potential value of more precise psychological assessment in research on prevention and intervention planning.

What to keep in mind

The review included only 12 papers, and the underlying populations were mixed clinical-forensic samples. Findings about the relationship between PDs and violent behavior were inconsistent.

Source

Published in Clin Ter. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.